All In Biotech

Drug Trial Radar · NCT07499362

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Phase 2, Single-arm Study to Investigate the Tolerability, Pharmacokinetics, Efficacy, and Safety of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Mar 26, 2026

Primary completion

Aug 22, 2028

Study completion Aug 22, 2028

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Mar 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT

Conditions

  • Tenosynovial Giant Cell Tumor

Interventions

  • PimicotinibDrug

    In the Safety Run-in Cohort, participants will receive 50 milligrams (mg) of pimicotinib once daily (QD), orally in 28-day cycles until disease progression (DP), death, discontinuation, or any other reason. The Safety Monitoring Committee (SMC) will monitor and assess tolerability of pimicotinib 50 mg QD during the safety run-in cohort. After making a recommendation about opening the Expansion Cohort based on the assessment in safety run-in cohort, participants will receive 50 mg of pimicotinib monotherapy QD, orally in 28-day cycles until disease progression (DP), death, discontinuation, or any other reason.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Run-In Cohort: Number of Participants with Dose Limiting Toxicity (DLT)-like eventsTime frame: Day 1 up to Day 28 of Cycle 1 (each cycle is of 28 days)
  2. Safety Run-In Cohort: Pharmacokinetic (PK) Plasma Concentration of PimicotinibTime frame: Pre-dose up to 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is of 28 days)
  3. Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review CommitteeTime frame: Time from first study treatment until progressive disease or death, assessed up to approximately 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center Hospital

    Chūōku, Japan · Recruiting

  • Kyushu University Hospital - 300173484

    Fukuoka, Japan · Recruiting

  • Kanazawa University Hospital

    Kanazawa, Japan · Recruiting

  • Cancer Institute Hospital of JFCR - Dept of Orthopedic Surgery

    Kōtoku, Japan · Recruiting

  • Nagoya University Hospital - 300176284

    Nagoya, Japan · Recruiting

  • Okayama University Hospital - Dept of Orthopedic Surgery

    Okayama, Japan · Recruiting

  • Osaka International Cancer Institute

    Osaka, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.